The Economist An end to litigation will probably revive talk of breaking up Bayer, a conglomerate short of synergies
An end to litigation will probably revive talk of breaking up Bayer, a conglomerate short of synergies
An end to litigation will probably revive talk of breaking up Bayer, a conglomerate short of synergies